Marinomed Biotech AG Approves Sale of Carragelose Division

Marinomed Biotech AG has announced the approval of the sale of its Carragelose business unit to Unither Pharmaceuticals. This decision, made during an extraordinary general meeting, received the required majority vote from shareholders. The transaction includes total payments up to EUR 20 million, but it remains conditional on certain regulatory approvals.

The sale is a strategic move for Marinomed, enabling the company to implement its restructuring plan and focus on the Marinosolv platform. Marinomed is shifting its attention to the commercialization of Budesolv and Tacrosolv, alongside expanding its Solv4U service offerings.

Additionally, Dr. Karl Mahler was elected to the Supervisory Board, bringing extensive experience from his tenure at Hoffman La Roche. The board now comprises four members. The company is optimistic about its future and is committed to achieving profitability with shareholder support.